Myofibroblasts: the ideal target to prevent arteriovenous fistula failure?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24487362.
- Also identified by DOI 10.1038/ki.2013.384.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The arteriovenous fistula (AVF) failure is a major cause of morbidity in the hemodialysis population. Most AVFs fail due to neointimal hyperplasia (NIH). In this issue, Yang et al. delineated a mechanism responsible for transforming the fistula adventitia into a fertile soil for neointimal precursors. These authors pondered the role of hypoxia-regulated hypoxia-inducible factor-1 (HIF-1α), vascular endothelial growth factor A (VEGF-A), and matrix metalloproteinases (MMPs) in the activation of those adventitial myofibroblasts that may significantly contribute to the formation of the fistula neointima.
Medical subject headings
- Adventitia
- Arteriovenous Shunt, Surgical
- Genetic Therapy
- Genetic Vectors
- Graft Occlusion, Vascular
- Jugular Veins
- Lentivirus
- RNA Interference
- RNA, Small Interfering
- Transduction, Genetic
- Vascular Endothelial Growth Factor A